My NCBI | Sign In
RSS Settings
  • Search: Veldt BJ[au]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 16

    1.

    Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C.

    Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Rosen CB, Heimbach JK, Janssen HL, Charlton MR.

    Am J Transplant. 2009 Jun;9(6):1406-13. Epub 2009 May 13.PMID: 19459812 [PubMed - in process]Related articles

    2.

    Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection.

    Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, Rosen CB, Heimbach JK, Charlton MR.

    Am J Transplant. 2008 Nov;8(11):2426-33. Epub 2008 Aug 22.PMID: 18727694 [PubMed - indexed for MEDLINE]Related articles

    3.

    Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus.

    Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, de Knegt RJ, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL.

    Hepatology. 2008 Jun;47(6):1856-62.PMID: 18506898 [PubMed - indexed for MEDLINE]Related articles

    4.

    Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

    Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL.

    Ann Intern Med. 2007 Nov 20;147(10):677-84.PMID: 18025443 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C.

    Veldt BJ, van der Vliet HJ, von Blomberg BM, van Vlierberghe H, Gerken G, Nishi N, Hayashi K, Scheper RJ, de Knegt RJ, van den Eertwegh AJ, Janssen HL, van Nieuwkerk CM.

    J Hepatol. 2007 Sep;47(3):356-65. Epub 2007 Jun 6.PMID: 17599630 [PubMed - indexed for MEDLINE]Related articles

    6.

    Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon.

    Veldt BJ, Schalm SW, Janssen HL.

    J Clin Gastroenterol. 2007 Apr;41(4):432. No abstract available. PMID: 17413616 [PubMed - indexed for MEDLINE]Related articles

    7.

    Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.

    Lukasiewicz E, Hellstrand K, Westin J, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Veldt BJ, Hansen BE, Verhey-Hart E, Lagging M.

    Hepatology. 2007 Jan;45(1):258-9. No abstract available. PMID: 17187414 [PubMed - indexed for MEDLINE]Related articles

    8.

    Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon.

    Veldt BJ, Hansen BE, Ikeda K, Verhey E, Suzuki H, Schalm SW.

    Scand J Gastroenterol. 2006 Sep;41(9):1087-94.PMID: 16938723 [PubMed - indexed for MEDLINE]Related articles

    9.

    Loss of vision as a presenting sign of cobalamin deficiency: An eye-opener.

    Veldt BJ, Zuidgeest DM, de Beijer-Dominicus JA, Dees A.

    Eur J Intern Med. 2006 Jul;17(4):292-4.PMID: 16762783 [PubMed - in process]Related articles

    10.

    Dynamic decision analysis to determine optimal treatment duration in chronic hepatitis C.

    Veldt BJ, Hansen BE, Eijkemans MJ, de Knegt RJ, Stijnen T, Habbema JD, Schalm SW.

    Aliment Pharmacol Ther. 2005 Mar 1;21(5):539-47.PMID: 15740537 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

    Veldt BJ, Saracco G, Boyer N, Cammà C, Bellobuono A, Hopf U, Castillo I, Weiland O, Nevens F, Hansen BE, Schalm SW.

    Gut. 2004 Oct;53(10):1504-8. Review.PMID: 15361504 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    The treatment of hepatitis C: history, presence and future.

    Vrolijk JM, de Knegt RJ, Veldt BJ, Orlent H, Schalm SW.

    Neth J Med. 2004 Mar;62(3):76-82. Review.PMID: 15209471 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Hepatitis C 2002 guidelines: summary and annotations.

    Orlent H, Vrolijk JM, Veldt BJ, Schalm SW.

    Scand J Gastroenterol Suppl. 2003;(239):105-10. Review.PMID: 14743892 [PubMed - indexed for MEDLINE]Related articles

    14.

    Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378].

    Veldt BJ, Brouwer JT, Adler M, Nevens F, Michielsen P, Delwaide J, Hansen BE, Schalm SW; Benelux Study Group on Treatment of Chronic Hepatitis C.

    BMC Gastroenterol. 2003 Aug 29;3:24.PMID: 12948399 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Hepatosplenic gammadelta T cell lymphoma: a diagnostic pitfall.

    Veldt BJ, Meijers C, Zondervan PE, de Man RA.

    J Hepatol. 2003 Sep;39(3):455-7. No abstract available. Erratum in: J Hepatol. 2004 Feb;40(2):365. PMID: 12927937 [PubMed - indexed for MEDLINE]Related articles

    16.

    Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing.

    Veldt BJ, Lainé F, Guillygomarc'h A, Lauvin L, Boudjema K, Messner M, Brissot P, Deugnier Y, Moirand R.

    J Hepatol. 2002 Jan;36(1):93-8.PMID: 11804670 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    2 free full-text articles in PubMed Central

    Find related data

    Search details

    » See more...

    Recent activity